Pharmaceutical giant Pfizer is in contact with Israeli companies Gamida Cell and TEVA, with intent of commercializing Gamida Cell’s StemEX, a treatments for lymphoma and leukemia (which is partially owned by TEVA). Israeli economics magazine Calcalist reports that if the deal goes through, Gamida cell will receive tens of millions of dollars in advance plus grants for milestones reached. Gamida Cell specializes in developing stem cell therapy projects.
Related posts
A Promising Treatment For Trauma-Induced Fibromyalgia
March 23, 2023
Generative AI Startup Helps Developers Test Code Logic
March 23, 2023
Cream Cheese And Cheddar Cheese – Made From Chickpeas
March 22, 2023
$8M For Startup That Digitizes The Construction Supply Chain
March 22, 2023
Facebook comments